Cargando…

Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake

High expression of prostate-specific membrane antigen (PSMA) in prostate cancers prompted the development of the PSMA-targeted PET-imaging agent [(18)F]DCFPyL, which was recently approved by the FDA. Fluorine-18-labeled Lys–Urea–Glu-based oxime derivatives of [(18)F]DCFPyL were prepared for the comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basuli, Falguni, Phelps, Tim E., Zhang, Xiang, Woodroofe, Carolyn C., Roy, Jyoti, Choyke, Peter L., Swenson, Rolf E., Jagoda, Elaine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144807/ https://www.ncbi.nlm.nih.gov/pubmed/35631423 http://dx.doi.org/10.3390/ph15050597

Ejemplares similares

Automated Synthesis of Fluorine-18 Labeled CXCR4 Ligand via the Conjugation with Nicotinic Acid N-Hydroxysuccinimide Ester (6-[(18)F]SFPy)
por: Basuli, Falguni, et al.
Publicado: (2020)

Fluorine-18 Labeled Fluorofuranylnorprogesterone ([(18)F]FFNP) and Dihydrotestosterone ([(18)F]FDHT) Prepared by “Fluorination on Sep-Pak” Method
por: Basuli, Falguni, et al.
Publicado: (2019)

Synthesis and Evaluation of Fluorine-18-Labeled L-Rhamnose Derivatives
por: Zhang, Xiang, et al.
Publicado: (2023)

Radiosynthesis of 5-[(18)F]Fluoro-1,2,3-triazoles through Aqueous Iodine–[(18)F]Fluorine Exchange Reaction
por: Zhang, Xiang, et al.
Publicado: (2021)

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
por: Jagoda, Elaine M., et al.
Publicado: (2019)

Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

GCP III is not the “off-target” for urea-based PSMA ligands
por: Lee, Zhenghong, et al.
Publicado: (2023)

Design, Synthesis, Computational, and Preclinical Evaluation of (nat)Ti/(45)Ti-Labeled Urea-Based Glutamate PSMA Ligand
por: Søborg Pedersen, Kristina, et al.
Publicado: (2020)

The effect of eating on the uptake of PSMA ligands in the salivary glands
por: Mohan, V., et al.
Publicado: (2021)

Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer
por: Guo, Yirui, et al.
Publicado: (2021)

Optimized (68)Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands
por: Kuo, Hsiou-Ting, et al.
Publicado: (2023)

Repurposing the Pummerer Rearrangement: Determination of Methionine Sulfoxides in Peptides
por: Woodroofe, Carolyn C., et al.
Publicado: (2019)

Synthesis of [(18)F]Favipiravir and Biodistribution in C3H/HeN Mice as Assessed by Positron Emission Tomography
por: Bocan, Thomas M., et al.
Publicado: (2019)

Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain
por: Syvänen, Stina, et al.
Publicado: (2020)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
por: Mohan, V., et al.
Publicado: (2021)

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
por: Gaertner, Florian C., et al.
Publicado: (2017)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

In Vitro Cellular Uptake Studies of Self-Assembled Fluorinated Nanoparticles Labelled with Antibodies
por: Atabakhshi-Kashi, Mona, et al.
Publicado: (2021)

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
por: Zhou, Haoxi, et al.
Publicado: (2021)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A
por: Whitlock, Nichelle C., et al.
Publicado: (2022)

Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [(68)Ga]Ga-PSMA-11
por: Nail, Vincent, et al.
Publicado: (2022)

A perspective on the EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands
por: Gericke, Germo
Publicado: (2021)

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
por: Huang, Steve S., et al.
Publicado: (2017)

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
por: Wirtz, Martina, et al.
Publicado: (2018)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
por: Sjögreen Gleisner, Katarina, et al.
Publicado: (2022)

Optimized Therapeutic (177)Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

Characterization of Brain Inflammation, Apoptosis, Hypoxia, Blood-Brain Barrier Integrity and Metabolism in Venezuelan Equine Encephalitis Virus (VEEV TC-83) Exposed Mice by In Vivo Positron Emission Tomography Imaging
por: Bocan, Thomas M., et al.
Publicado: (2019)

Targeting USP-7 by a Novel Fluorinated 5-Pyrazolyl-Urea Derivative
por: Morretta, Elva, et al.
Publicado: (2023)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Preclinical evaluation and first in human study of Al(18)F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer
por: Ren, Ya’nan, et al.
Publicado: (2022)

[(18)F]DPA-714 PET Imaging Reveals Global Neuroinflammation in Zika Virus-Infected Mice
por: Kuszpit, Kyle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7hi506f6n9kfkqqvqrjkos66na